down arrow

NRX Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6294441000
USD
2.44
0.17 (7.49%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.362.51

52 Week

1.156.01
Valuation
Technical
Day's Volume

CASH

356.71 k

Shareholding (Mar 2025)

FII

0.61%

Held by 7 FIIs

DII

94.52%

Held by 5 DIIs

Promoter

0.00%

How big is NRX Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, NRX Pharmaceuticals, Inc. has a market capitalization of 57.75 million, with net sales of 0.00 million and a net profit of -24.11 million over the last four quarters. The company reported shareholder's funds of -23.22 million and total assets of 3.65 million as of Dec 24.

Market Cap: As of Jun 18, NRX Pharmaceuticals, Inc. has a market capitalization of 57.75 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, NRX Pharmaceuticals reported net sales of 0.00 million and a net profit of -24.11 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -23.22 million and total assets of 3.65 million.

Read More

What does NRX Pharmaceuticals, Inc. do?

22-Jun-2025

NRX Pharmaceuticals, Inc. is a blank check company in the Pharmaceuticals & Biotechnology sector focused on business combinations. It has a market cap of $57.75 million and reported a net profit loss of $6 million as of March 2025.

Overview:<BR>NRX Pharmaceuticals, Inc. is a blank check company in the Pharmaceuticals & Biotechnology industry, formed for the purpose of engaging in business combinations.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 57.75 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.11<BR>Return on Equity: 72.66%<BR>Price to Book: -2.30<BR><BR>Contact Details:<BR>Address: 2645 N Federal Hwy Ste 230, DELRAY BEACH FL: 33483-6111<BR>Tel: 1 310 7342300<BR>Fax: 1 302 6555049<BR>Website: https://www.bigrockpartners.com/spac/spac_aboutus.html

Read More

Is NRX Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of July 7, 2025, NRX Pharmaceuticals shows a mildly bullish trend with positive short-term indicators, despite mixed signals from MACD and some bearishness on the weekly timeframe, while outperforming the S&P 500 in various timeframes but underperforming over the long term.

As of 7 July 2025, the technical trend for NRX Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are bullish for both weekly and monthly time frames, and the daily moving averages are bullish, supporting a positive short-term outlook. However, the KST and OBV show mild bearishness on the weekly, with Dow Theory indicating no trend. <BR><BR>In terms of performance, NRX Pharmaceuticals has outperformed the S&P 500 over the past week (3.47% vs. 1.05%), month (7.97% vs. 2.33%), year-to-date (35.45% vs. 12.22%), and year (83.95% vs. 17.14%), but has significantly underperformed over the 3-year and 5-year periods. Overall, the current technical stance is mildly bullish, driven by the daily moving averages and Bollinger Bands, despite some bearish indicators on the weekly timeframe.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 68 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.21

stock-summary
Return on Equity

39.64%

stock-summary
Price to Book

-1.90

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.15%
0%
-6.15%
6 Months
-10.29%
0%
-10.29%
1 Year
93.65%
0%
93.65%
2 Years
-33.51%
0%
-33.51%
3 Years
76.81%
0%
76.81%
4 Years
-95.56%
0%
-95.56%
5 Years
-77.61%
0%
-77.61%

NRX Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is NRX Pharmaceuticals, Inc. technically bullish or bearish?

As of 7 July 2025, the technical trend for NRX Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are bullish for both weekly and monthly time frames, and the daily moving averages are bullish, supporting a positive short-term outlook. However, the KST and OBV show mild bearishness on the weekly, with Dow Theory indicating no trend. In terms of performance, NRX Pharmaceuticals has outperformed the S&P 500 over the past week (3.47% vs. 1.05%), month (7.97% vs. 2.33%), year-to-date (35.45% vs. 12.22%), and year (83.95% vs. 17.14%), but has significantly underperformed over the 3-year and 5-year periods. Overall, the current technical stance is mildly bullish, driven by the daily moving averages and Bollinger Bands, despite some bearish indicators on the weekly timeframe....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-266.90%
EBIT to Interest (avg)
-16.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.74%
ROCE (avg)
0
ROE (avg)
0.23%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.25
EV to EBIT
-3.40
EV to EBITDA
-3.40
EV to Capital Employed
-2.66
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (4.87%)

Foreign Institutions

Held by 7 Foreign Institutions (0.61%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -122.78% vs 9.20% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.70",
          "val2": "-7.00",
          "chgp": "47.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.80",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.90",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.60",
          "val2": "-7.90",
          "chgp": "-122.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.61% vs 24.37% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.70",
          "val2": "-27.60",
          "chgp": "28.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "0.10",
          "chgp": "1,000.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.40",
          "val2": "-2.90",
          "chgp": "-51.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.10",
          "val2": "-30.10",
          "chgp": "16.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.70
-7.00
47.14%
Interest
0.00
0.80
-100.00%
Exceptional Items
-13.90
-0.00
Consolidate Net Profit
-17.60
-7.90
-122.78%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -122.78% vs 9.20% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-19.70
-27.60
28.62%
Interest
1.10
0.10
1,000.00%
Exceptional Items
-4.40
-2.90
-51.72%
Consolidate Net Profit
-25.10
-30.10
16.61%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 16.61% vs 24.37% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About NRX Pharmaceuticals, Inc. stock-summary
stock-summary
NRX Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Big Rock Partners Acquisition Corp. is a blank check company. The Company is formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The Company is not limited to a particular industry or geographic region for purposes of consummating a business combination. The Company has not commenced any business operation and has not generated any revenue.
Company Coordinates stock-summary
Company Details
2645 N Federal Hwy Ste 230 , DELRAY BEACH FL : 33483-6111
stock-summary
Tel: 1 310 7342300
stock-summary
https://www.bigrockpartners.com/spac/spac_aboutus.html
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."